Tsinkayar cutar kansa ta prostate ta dogara da dalilai da yawa, gami da matakin cutar kansa, shekarun mai haƙuri da lafiyar gaba ɗaya, da kuma mummunan ƙwayoyin cutar kansa.
Gabaɗaya, cutar kansa tana da kyakkyawan tsinkaye, musamman idan aka gano ta da wuri.
Yawan shekarun rayuwa na shekaru 5 don cutar sankarar mahaifa (ciwon daji wanda bai bazu ba bayan prostate) ya kusan 100%.
Yana da mahimmanci a tattauna takamaiman hangen nesa tare da ƙwararren likita, saboda yana iya bambanta sosai daga mutum zuwa mutum.
Yang X, Wang R, Xu K, Yang F, Chen Y, Zuo Z, Song B: [Knockdown of myeloid cell leukemia 1 gene inhibits the proliferation and promotes apoptosis of prostate cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017, 33 (1): 62-66.
Kubota Y, Ito K, Imai K, Yamanaka H: Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate. 2002, 50 (4): 262-9.
Li K, Zhou H, Wang F, Zhao C, Fan C, Wang J: ZBTB38 suppresses prostate cancer cell proliferation and migration via directly promoting DKK1 expression. Cell Death Dis. 2021, 12 (11): 998.
Sun HF, Wang WD, Feng L: Effect of SPAG9 on migration, invasion and prognosis of prostate cancer. Int J Clin Exp Pathol. 2017, 10 (9): 9468-9474.
Xia Q, Li J, Yang Z, Zhang D, Tian J, Gu B: Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer. Medicine (Baltimore). 2020, 99 (7): e18993.
Dong L, Ding H, Li Y, Xue D, Li Z, Liu Y, Zhang T, Zhou J, Wang P: TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer. Int J Biol Macromol. 2019, 121 (): 200-206.
Rucci N, Angelucci A: Prostate cancer and bone: the elective affinities. Biomed Res Int. 2014, 2014 (): 167035.
['Bayanin sanarwa: likita']
['Wannan shafin yanar gizon don ilimantarwa ne kawai ba don ba da shawara ko kuma ba da shawara ta likita ba.']
['Bai kamata a yi amfani da bayanin da aka bayar don gano ko magance matsalar lafiya ko cuta ba, kuma waɗanda suke neman shawarar likita na sirri ya kamata su tuntuɓi likitan da ke da lasisi.']
['Lura cewa hanyar sadarwar jijiyoyin da ke samar da amsoshin tambayoyin, ba ta da daidaito musamman idan ya zo ga abun cikin lamba. Misali, yawan mutanen da aka gano suna da takamaiman cuta.']
["Koyaushe nemi shawarar likitanka ko wani ƙwararren mai ba da lafiya game da yanayin likita. Kada ka taɓa yin watsi da shawarar likita ko jinkiri wajen neman ta saboda wani abu da ka karanta a wannan rukunin yanar gizon. Idan kuna tsammanin kuna da matsalar gaggawa ta likita, kira 911 ko je zuwa ɗakin gaggawa mafi kusa nan da nan. Babu wata alaƙar likita da mara lafiya da aka ƙirƙira ta wannan rukunin yanar gizon ko amfaninsa. BioMedLib ko ma'aikatanta, ko kowane mai ba da gudummawa ga wannan rukunin yanar gizon, ba su yin kowane wakilci, bayyane ko a bayyane, dangane da bayanan da aka bayar a nan ko amfaninsa."]
['Bayanin haƙƙin mallaka']
['Dokar haƙƙin mallaka ta Millennium ta 1998, 17 U.S.C. § 512 (DMCA) tana ba da damar neman masu haƙƙin mallaka waɗanda suka yi imanin cewa kayan da ke bayyana a Intanet sun keta haƙƙinsu a ƙarƙashin dokar haƙƙin mallaka ta Amurka. ']
['Idan kun yi imani da gaskiya cewa duk wani abun ciki ko kayan da aka samar dangane da gidan yanar gizon mu ko ayyukanmu ya keta haƙƙin mallaka, ku (ko wakilin ku) na iya aiko mana da sanarwa don neman cire abun ciki ko kayan, ko toshe damar zuwa gare shi. ']
["Dole ne a aika da sanarwa a rubuce ta hanyar imel (duba sashin 'Saduwa' don adireshin imel). "]
['DMCA tana buƙatar sanarwar ku game da zargin keta haƙƙin mallaka ya haɗa da waɗannan bayanan: (1) bayanin aikin haƙƙin mallaka wanda shine batun zargin cin zarafin; (2) bayanin abin da ake zargi da cin zarafin abun ciki da kuma isasshen bayani don ba mu damar gano abun ciki; (3) bayanin tuntuɓar ku, gami da adireshin ku, lambar tarho da adireshin imel; (4) sanarwa daga gare ku cewa kuna da kyakkyawan imani cewa abun cikin yadda ake korafin ba shi da izinin mai haƙƙin mallaka, ko wakilinsa, ko ta aikin kowace doka; ']
['(5) sanarwa daga gare ku, wanda aka sanya hannu a ƙarƙashin hukuncin shaidar zur, cewa bayanin da ke cikin sanarwar daidai ne kuma kuna da ikon aiwatar da haƙƙin mallaka wanda ake zargin an keta shi; ']
['da (6) sa hannu na zahiri ko na lantarki na mai haƙƙin mallaka ko mutumin da aka ba shi izinin yin aiki a madadin mai haƙƙin mallaka. ']
['Rashin hada dukkan bayanan da ke sama na iya haifar da jinkiri wajen aiwatar da korafin ka.']
['Tuntuɓi']
['Da fatan za a aiko mana da imel tare da kowace tambaya / shawara.']
What is prognosis of prostate cancer?
The prognosis of prostate cancer depends on several factors, including the stage of the cancer, the patient's age and overall health, and the aggressiveness of the cancer cells.
In general, prostate cancer has a good prognosis, especially when caught early.
The 5-year survival rate for localized prostate cancer (cancer that has not spread beyond the prostate) is nearly 100%. However, the prognosis worsens as the cancer progresses and spreads to other parts of the body.
It is important to discuss the specific prognosis with a healthcare professional, as it can vary greatly from person to person.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Game da']
["BioMedLib yana amfani da kwamfutoci na atomatik (algorithms na koyon inji) don samar da nau'ikan tambaya da amsa."]
['Mun fara da wallafe-wallafen likitancin halittu miliyan 35 na PubMed/Medline. Har ila yau, shafukan yanar gizo na RefinedWeb.']
